Barrington Research Maintains Outperform on Bioventus, Raises Price Target to $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barrington Research analyst Michael Petusky maintains Bioventus (NASDAQ:BVS) with a Outperform and raises the price target from $13 to $14.
Barrington Research analyst Michael Petusky maintains Bioventus (NASDAQ:BVS) with a Outperform and raises the price target from $13 to $14.